Insmed Corp (INSM) Enterprise Value to EBITDA Ratio

Patient loyalty to therapies for rare lung pathologies has triggered a sharp rise in share prices for Insmed Incorporated (INSM), a trend reflected in the EV/EBITDA multiple. The current value is 0.00. Business resilience is supported by partnerships with scientific centers and rigorous quality control of outsourced drug manufacturing. This approach minimizes risks when scaling innovations within a narrow medical segment.

Insmed Inc. - INSM Company Value to EBITDA (period 11/23/2025 - 11/11/2026)

Comprehensive metric breakdowns and analytics for insmed.com (INSM)

- current price and projected stock value:

Stock Price Insmed Inc|INSM - Analyst Median Target

- market capitalization details:

Market Valuation Insmed Corp|INSM - Full Business Value

- business book valuation details:

Book Value per Share Insmed|INSM - Total Stockholders' Equity|Market Capitalization to Book Value Ratio insmed.com|INSM - Total Business Assets

- debt burden and liquidity indicators:

- financial results and valuation multiples details:

INSM - Final Profit|Expected Profit Insmed Incorporated|INSM - Price to Earnings Ratio|Forward P/E Multiple Insmed Incorporated|INSM - PEG Multiple|EV/EBITDA Multiple Insmed Corp|INSM - Operating income before deduction of amortization|Earnings per share for the last twelve months Insmed|INSM - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months insmed.com|INSM - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Insmed Incorporated

Fundamental valuation:Insmed Inc INSM

The EV/EBITDA ratio determines business value by combining market capitalization and net debt while excluding the impact of taxes and depreciation. An investor compares this metric with operational efficiency to identify asset overvaluation. By analyzing the EV/EBITDA trajectory, one can observe value accumulation phases preceding fundamental breakthroughs. For Insmed Incorporated (INSM), such a valuation confirms the investment attractiveness of their unique scientific expertise in the therapy of rare lung diseases.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|UTHR: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio BMRN|BBIO: EV/EBITDA Multiple|Company Value to EBITDA BGM Group (BGM)|COGT (Cogent Bio) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XERS (Xeris Pharma)|Enterprise Value to EBITDA Ratio KROS (Keros Therapeutics)|ARCT (arcturusrx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eton Pharmaceuticals, Inc. ETON|KMDA (Kamada Ltd) - Company Value to Operating Income Before Depreciation Ratio|Fulcrum Tx - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ABEO (Abeona Therapeutics)|MREO: EV/EBITDA Multiple|protalix.com (PLX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pliant Therapeutics Inc|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rein Therapeutics, Inc. (RNTX)|Enterprise Value to EBITDA Ratio gelteq.com GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma)|EV/EBITDA Multiple Chemomab Therapeutics Ltd CMMB|SRx Health - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Polyrizon Ltd PLRZ|zentaris.com (AEZS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CYTH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|reneopharma.com (RPHM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization COSCIENS Biopharma (CSCI)